Suppr超能文献

肿瘤抑制因子p16(一种锚蛋白样重复蛋白)的结构特征

Structural characterization of the tumor suppressor p16, an ankyrin-like repeat protein.

作者信息

Boice J A, Fairman R

机构信息

Division of Macromolecular Structure, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.

出版信息

Protein Sci. 1996 Sep;5(9):1776-84. doi: 10.1002/pro.5560050903.

Abstract

The p16 protein has been identified as a tumor suppressor that functions by inhibiting the cyclin-dependent kinases CDK4 and CDK6. Deletions or point mutations in the p16 gene have been found in a number cancers, emphasizing its importance in regulating cell cycle progression. Inhibition by p16 occurs through protein-protein interactions with its targets. This is not surprising, since p16 is thought to contain ankyrin-like repeats, motifs implicated in protein-protein interactions. Our goal was to identify structural characteristics of p16 not only as an important step towards understanding CDK4 inhibition but also to explore the role of ankyrin repeats in the p16 structure, as no detailed structure of any protein containing these motifs has been reported. We have expressed, refolded, and purified p16 from E. coli and have shown it to be functionally active by specific binding to CDK4. Analytical ultracentrifugation has shown that p16 weakly self-associates to form dimers with a Kd = 270 microM. The CD spectrum indicates that the protein is composed of 33% alpha-helix, 22% beta-sheet, 19% beta-turn, and 27% other (which includes aromatic and random coil contributions). Further CD experiments suggest that p16 exhibits low structural stability with a delta G of -2.3 kcal/mol. This weak stability is a consequence of a highly dynamic structure as measured by ANS-binding, NMR hydrogen-deuterium exchange, and fluorescence. It is possible that a well-defined tertiary structure is imparted upon the binding of p16 to CDK4.

摘要

p16蛋白已被鉴定为一种肿瘤抑制因子,其作用机制是抑制细胞周期蛋白依赖性激酶CDK4和CDK6。在多种癌症中都发现了p16基因的缺失或点突变,这凸显了其在调节细胞周期进程中的重要性。p16的抑制作用是通过与其靶标进行蛋白质-蛋白质相互作用实现的。这并不奇怪,因为p16被认为含有锚蛋白样重复序列,这些基序与蛋白质-蛋白质相互作用有关。我们的目标是确定p16的结构特征,这不仅是理解CDK4抑制作用的重要一步,也是探索锚蛋白重复序列在p16结构中的作用,因为尚未有包含这些基序的任何蛋白质的详细结构报道。我们已经从大肠杆菌中表达、复性并纯化了p16,并通过与CDK4的特异性结合证明其具有功能活性。分析超速离心表明,p16以Kd = 270 microM的亲和力弱自缔合形成二聚体。圆二色光谱表明,该蛋白由33%的α-螺旋、22%的β-折叠、19%的β-转角和27%的其他结构(包括芳香族和无规卷曲结构)组成。进一步的圆二色实验表明,p16的结构稳定性较低,ΔG为-2.3 kcal/mol。这种较弱的稳定性是由ANS结合、核磁共振氢氘交换和荧光测量所显示的高度动态结构导致的。p16与CDK4结合时可能会赋予其明确的三级结构。

相似文献

引用本文的文献

3
Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.CDK4/6 抑制剂在肾细胞癌中的治疗潜力。
Nat Rev Urol. 2022 May;19(5):305-320. doi: 10.1038/s41585-022-00571-8. Epub 2022 Mar 9.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验